Simmerafil is a selective phosphodiesterase type 5 (PDE5) inhibitor currently under development for the treatment of erectile dysfunction and pulmonary arterial hypertension. By inhibiting the PDE5 enzyme,… Read more
Simmerafil is a selective phosphodiesterase type 5 (PDE5) inhibitor currently under development for the treatment of erectile dysfunction and pulmonary arterial hypertension. By inhibiting the PDE5 enzyme, this therapeutic agent modulates the cyclic GMP pathway to facilitate vasodilation and improve blood flow. This category provides a comprehensive selection of high-quality materials to support rigorous analytical development and regulatory compliance. The collection includes pharmaceutical reference standards for the Simmerafil API, along with essential tools for impurity profiling, such as specified degradation products and metabolites. Additionally, stable isotope labelled compounds are available to provide precise internal standards for mass spectrometry and quantitative analysis. These reference materials are critical for laboratories conducting method validation, stability testing, and routine quality control of this small molecule compound throughout its development lifecycle, ensuring accuracy and reliability in scientific research and pharmaceutical monitoring.